JP2020513041A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020513041A5 JP2020513041A5 JP2020504468A JP2020504468A JP2020513041A5 JP 2020513041 A5 JP2020513041 A5 JP 2020513041A5 JP 2020504468 A JP2020504468 A JP 2020504468A JP 2020504468 A JP2020504468 A JP 2020504468A JP 2020513041 A5 JP2020513041 A5 JP 2020513041A5
- Authority
- JP
- Japan
- Prior art keywords
- mucus
- subject
- alkyl
- nitric oxide
- releasing biopolymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 64
- 210000003097 mucus Anatomy 0.000 claims 36
- 229920001222 biopolymer Polymers 0.000 claims 23
- 239000003607 modifier Substances 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 239000002840 nitric oxide donor Substances 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 244000052769 pathogen Species 0.000 claims 4
- 241000186359 Mycobacterium Species 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 229920000715 Mucilage Polymers 0.000 claims 2
- 239000000853 adhesive Substances 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 230000000844 anti-bacterial effect Effects 0.000 claims 2
- 230000000845 anti-microbial effect Effects 0.000 claims 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000003232 mucoadhesive effect Effects 0.000 claims 2
- 230000000510 mucolytic effect Effects 0.000 claims 2
- 239000002953 phosphate buffered saline Substances 0.000 claims 2
- MUMXDRRTIYLYMY-YJKCNMNRSA-N (Z)-[dodecyl-[6-(dodecylazaniumyl)hexyl]amino]-oxido-oxidoiminoazanium Chemical compound CCCCCCCCCCCC[NH2+]CCCCCCN(CCCCCCCCCCCC)[N+](\[O-])=N\[O-] MUMXDRRTIYLYMY-YJKCNMNRSA-N 0.000 claims 1
- 241001673062 Achromobacter xylosoxidans Species 0.000 claims 1
- 241000589513 Burkholderia cepacia Species 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 241000588747 Klebsiella pneumoniae Species 0.000 claims 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- 241000122971 Stenotrophomonas Species 0.000 claims 1
- 206010000269 abscess Diseases 0.000 claims 1
- 125000005907 alkyl ester group Chemical group 0.000 claims 1
- 210000000621 bronchi Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
- 210000003437 trachea Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762483655P | 2017-04-10 | 2017-04-10 | |
| US62/483,655 | 2017-04-10 | ||
| PCT/IB2018/052522 WO2018189687A1 (en) | 2017-04-10 | 2018-04-10 | Compounds, compositions and methods for inhibiting a pathogen and/or modifying mucus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020513041A JP2020513041A (ja) | 2020-04-30 |
| JP2020513041A5 true JP2020513041A5 (enExample) | 2021-05-20 |
Family
ID=63792445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020504468A Pending JP2020513041A (ja) | 2017-04-10 | 2018-04-10 | 病原体の阻害および／または粘液の改変のための化合物、組成物、および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11324773B2 (enExample) |
| EP (1) | EP3592335A4 (enExample) |
| JP (1) | JP2020513041A (enExample) |
| CN (1) | CN110573143A (enExample) |
| WO (1) | WO2018189687A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11534382B2 (en) | 2017-06-19 | 2022-12-27 | Novan, Inc. | Topical compositions and methods of using the same |
| US11285171B2 (en) | 2018-03-01 | 2022-03-29 | Novan, Inc. | Nitric oxide releasing suppositories and methods of use thereof |
| CA3132400C (en) | 2019-03-18 | 2026-05-12 | Cedars-Sinai Medical Center | Compositions and methods to treat gastrointestinal diseases and disorders |
| CN115486478A (zh) * | 2022-10-09 | 2022-12-20 | 江苏天美健大自然生物工程有限公司 | 一种蛋白饮料用防腐剂组合物及其制备方法 |
| CN122477047A (zh) * | 2023-08-28 | 2026-07-28 | 卡尔罗伊健康科学有限责任公司 | 保护和增强肠糖萼结构与功能完整性的组合物及方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5234933A (en) | 1991-10-31 | 1993-08-10 | Board Of Governors Of Wayne State University And Vanderbilt University | Cyclic hydroxamic acids |
| DE4210332C1 (enExample) | 1992-03-30 | 1993-07-15 | Gruenenthal Gmbh, 5100 Aachen, De | |
| US5238832A (en) | 1992-06-08 | 1993-08-24 | Board Of Governors Of Wayne State University | Aryl aliphatic acids |
| US5859058A (en) * | 1994-07-14 | 1999-01-12 | Glaxo Wellcome Inc. | Nitric oxide synthase inhibitors for inhibiting the production of airway mucas |
| US6180082B1 (en) | 1997-11-24 | 2001-01-30 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Method to enhance tissue accumulation of radiolabeled compounds |
| US6261594B1 (en) | 1998-11-25 | 2001-07-17 | The University Of Akron | Chitosan-based nitric oxide donor compositions |
| IT1303793B1 (it) * | 1998-11-27 | 2001-02-23 | Promefarm S R L | "composizione farmaceutica comprendente un composto organico donatoredi ossido nitrico (no)" |
| AU2005244079A1 (en) * | 2004-05-11 | 2005-11-24 | Pulmonox Technologies Corporation | The use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant |
| WO2009049208A1 (en) * | 2007-10-12 | 2009-04-16 | The University Of North Carolina At Chapel Hill | Use of nitric oxide to enhance the efficacy of silver and other topical wound care agents |
| GB201021186D0 (en) * | 2010-12-14 | 2011-01-26 | Novabiotics Ltd | Composition |
| CN106986952B (zh) * | 2012-08-17 | 2020-03-10 | 北卡罗来纳大学查珀尔希尔分校 | 水溶性的释放一氧化氮的聚葡糖胺和其用途 |
-
2018
- 2018-04-10 JP JP2020504468A patent/JP2020513041A/ja active Pending
- 2018-04-10 US US16/500,755 patent/US11324773B2/en active Active
- 2018-04-10 WO PCT/IB2018/052522 patent/WO2018189687A1/en not_active Ceased
- 2018-04-10 CN CN201880024184.1A patent/CN110573143A/zh active Pending
- 2018-04-10 EP EP18784598.7A patent/EP3592335A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020504778A5 (enExample) | ||
| Vasiliev | Chitosan-based vaccine adjuvants: incomplete characterization complicates preclinical and clinical evaluation | |
| Aelenei et al. | Tannic acid incorporation in chitosan-based microparticles and in vitro controlled release | |
| RU2495662C2 (ru) | Антимикробные композиции с контролируемым высвобождением для лечения ушных заболеваний | |
| JP6525455B2 (ja) | 免疫賦活活性を有するオリゴヌクレオチド含有複合体及びその用途 | |
| AU2010218108B2 (en) | Otic compositions useful for the treatment of infections of the internal and external ear in mammals | |
| JP2022516461A5 (enExample) | ||
| JP2023537609A5 (enExample) | ||
| JP4696256B2 (ja) | バンコマイシン耐性グラム陽性細菌用抗菌剤 | |
| EP2892517A1 (en) | Antimicrobial composition | |
| JP2016513688A5 (enExample) | ||
| BR112022025855A2 (pt) | Polímero, método de administração de um ou mais agentes de ácido nucleico terapêuticos, de diagnóstico ou profiláticos, ou combinações dos mesmos in vivo | |
| CN110787298B (zh) | 可同时负载no和抗生素用于协同抗菌的星型中空纳米材料的制备与应用 | |
| JP2006516988A (ja) | 持続した薬物放出またはムコ粘着のための活性剤およびキトサンを含む製薬組成物 | |
| JP2020515688A5 (enExample) | ||
| JP2010527960A5 (enExample) | ||
| US8329155B2 (en) | Quaternary ammonium functionalized glycodendrimers, methods for the production and use thereof | |
| Chee et al. | Biomaterial therapeutic strategies for treatment of bacterial lung infections | |
| JP2025515314A5 (enExample) | ||
| EP0003682B1 (en) | Process for solubilizing an insoluble drug and an aqueous solution prepared by this process | |
| CN108472313A (zh) | 用于治疗耳炎的组合物和方法 | |
| Zarena et al. | Dendrimer a new dimension in targeting biofilms | |
| WO2023235749A3 (en) | Rna adjuvants, methods and uses thereof | |
| KR102355774B1 (ko) | 글리콜 키토산 유도체를 포함하는 애주번트 조성물 | |
| US20210145861A1 (en) | Chitosan containing compositions and methods relating to same |